1	Duration and reliability of the silent period in individuals with spinal cord injury
2	Running title: Silent period in cervical SCI
3	Hannah Sfreddo <sup>a</sup> *, Jaclyn R. Wecht <sup>a</sup> *, Ola Alsalman <sup>a,b</sup> , Yu-Kuang Wu <sup>a,b</sup> , Noam Y. Harel <sup>a,b</sup>
4	
5	* These authors contributed equally to this work
6	
7	<sup>a</sup> , James J. Peters VA Medical Center, 130 West Kingsbridge Road, Bronx, New York 10468
8	USA
9	<sup>b</sup> , Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, New York
10	10029 USA
11	
12	Corresponding Author:
13	Noam Y. Harel, MD, PhD

- 14 718-584-9000 x1742 (p); 888-299-1965 (f); noam.harel@mssm.edu
- 15

16 **Design:** Observational.

17 **Objectives**: We aim to better understand the silent period (SP), an inhibitory counterpart to the

- 18 well-known motor evoked potential (MEP) elicited by transcranial magnetic stimulation (TMS), in
- 19 individuals with spinal cord injury (SCI).
- 20 **Setting:** Veterans Affairs Hospital in New York.

21 Methods: Electromyographic responses were measured in the target abductor pollicis brevis at

22 rest (TMS at 120% of resting motor threshold (RMT)) and during maximal effort (TMS at 110%

23 of RMT). Participants with chronic cervical SCI (n=9) and able-bodied volunteers (n=12)

24 underwent between 3-7 sessions of stimulation on separate days. The primary outcomes were

the magnitude and reliability of SP duration, resting and active MEP amplitudes, and RMT.

Results: SCI participants showed significantly lower MEP amplitudes compared to AB participants. SCI SP duration was not significantly different from AB SP duration. SP duration demonstrated reduced intra-participant variability within and across sessions compared with MEP amplitudes. SCI participants also demonstrated a higher prevalence of SP 'interruptions' compared to AB participants.

31 **Conclusions**: SP reflects a balance between corticospinal excitatory and inhibitory processes.

32 SP duration is more reliable within and across multiple sessions than MEP amplitude.

33

Keywords: Transcranial magnetic stimulation, motor evoked potential, silent period, spinal cord
 injury, reliability

36

# 37 **1 Introduction**

38 The motor evoked potential (MEP) amplitude in response to transcranial magnetic stimulation 39 (TMS) is one of the most commonly used outcome measures for tracking neurophysiology of 40 the corticospinal system. Spinal cord injury (SCI) reduces MEP amplitude in muscles below the 41 injury, reflecting reduced excitatory transmission across the spinal lesion. In contrast, 42 corticospinal inhibitory processes are comparatively understudied after SCI. The silent period 43 (SP) occurs upon TMS administration to the motor cortex during volitional contraction of a target 44 muscle on either the ipsilateral or contralateral side of stimulation. In contralateral SP elicitation, 45 the resulting MEP is followed by a period of electromyographic (EMG) suppression (silent period) usually lasting 100-300 milliseconds<sup>1-3</sup> (Figure 1). Whereas the ipsilateral SP depends 46 47 on corpus callosum-mediated interhemispheric inhibition, the contralateral SP reflects cortical 48 and corticospinal processes<sup>3,4</sup>.

49

Spinal inhibitory mechanisms contribute to the first ~50 ms of the SP through hyperpolarization and segmental recurrent inhibition of motor neurons<sup>1,3</sup>. Interneuronal gamma-aminobutyric acid (GABA)<sub>B</sub> plays a major role in mediating intracortical inhibition of pyramidal motor cortex neurons during the remainder of the SP<sup>2,5</sup>. This is most clearly demonstrated by the elongation of SP duration when baclofen, a specific GABA<sub>B</sub> receptor agonist, is delivered intrathecally<sup>6</sup>. However, studies of oral and intravenous baclofen have failed to demonstrate a significant effect on SP duration<sup>5,7,8</sup>.

57

Lesions of the nervous system may lengthen or shorten SP duration. Cerebral pathologies that lengthen SP include stroke<sup>9</sup>, epilepsy<sup>10</sup>, and depression<sup>11</sup>. Conversely, pathologies that shorten SP include bipolar disorder<sup>12</sup> and chronic neuropathic pain<sup>13</sup>.

61

Few prior studies have investigated SP in the SCI population, with mixed results<sup>7,14–17</sup>. It is not 62 vet fully elucidated whether SCI lengthens SP (perhaps due to decreased afferent feedback 63 64 from the periphery) or shortens SP (perhaps due to increased cortical or spinal segmental 65 excitability). Furthermore, the reliability of SP duration as an outcome metric in SCI relative to the more commonly used MEP amplitude is hardly known<sup>18</sup>. To further characterize this 66 67 potentially important neurophysiological measure in the SCI population, we compared 68 magnitude and variability of hand muscle SP durations, MEP thresholds, and MEP amplitudes 69 in individuals with chronic cervical SCI and able-bodied volunteers across multiple testing 70 sessions.

71

72

### 73 2 Methods

**2.1 Design** – This experiment was an exploratory post-hoc analysis of a larger study in which we tested a novel configuration for non-invasive cervical transcutaneous spinal stimulation in individuals with and without cervical SCI (clinicaltrials.gov NCT02469675)<sup>19</sup>. SCI participants were eligible if they had traumatic or non-traumatic SCI between segments C2-C8 with any evidence for partially retained movement of finger extension, finger flexion, or finger abduction of either hand. Potential participants were excluded if they had risk factors for seizures or if they

had frequent episodes of autonomic dysreflexia. Participants provided informed consent before
initiating testing. All procedures were approved by the Institutional Review Board of the James
J. Peters VA Medical Center, Bronx, NY. All applicable institutional and governmental
regulations concerning the ethical participation of human volunteers were followed during this
research.

85

86 2.3 General Procedure - Neurological examination of motor and sensory function was 87 performed according to the International Standards for the Neurological Classification of Spinal 88 Cord Injury (ISNCSCI). Sessions were performed on separate days at a consistent time of day 89 per participant. Stimulation was delivered with participants in a seated upright position in an 90 adjustable TMS treatment chair (Magventure), or for one participant, in her own wheelchair. For 91 participants without neurological injury, TMS was targeted toward the dominant hand. For those 92 with SCI, TMS was targeted toward the hand with lower motor thresholds and more consistent 93 electrophysiological responses to central and peripheral stimulation. Arms and hands were 94 pronated and relaxed on a cushion placed in the participant's lap. Participants were not asked to 95 withhold their routine daily medications.

96

97 2.4 Transcranial Magnetic Stimulation (TMS) – A MagPro R30 or X100 system (Magventure, 98 Farum Denmark) with 80mm winged coil (D-B80) was used. The magnet was oriented at a 45-99 degree angle from the sagittal plane, centered over the hand motor cortex hotspot for maximal 100 APB response. The first six participants wore reusable cloth headcaps upon which the hotspot 101 was labeled with a marker in relation to the vertex. Our laboratory obtained an optical-based

102 neural navigation system (Brainsight, Rogue Research, Montreal, Canada) that was used to 103 track hotspots for the final 15 participants. There was no significant difference in session-to-104 session variability of any TMS measure with or without neural navigation. RMT was determined 105 as the percent of maximal stimulator output required to elicit an MEP in the APB muscle of at 106 least 50  $\mu$ V in 5 out of 10 repetitions.

107

108 2.5 Electromyographic Data – EMG of the target APB was recorded using surface sensors 109 with 300x preamplification, 15-2,000 Hz bandwidth, and internal grounding (Motion Lab Systems 100 Z03-002, Baton Rouge, Louisiana, USA). EMG was collected at a sample rate of 5,000 Hz via 111 digital acquisition board and customized LabVIEW software (National Instruments USB-6363, 112 Austin, Texas, USA). All EMG data were acquired and quantified using custom LabVIEW 113 scripts.

114

115 2.6 Eliciting and Measuring the Silent Period (SP) - While participants pinched a 116 dynamometer (Tracker Freedom, J-Tech, Salt Lake City, Utah, USA) between their thumb and 117 third finger using maximal effort, a single biphasic TMS pulse was delivered over the hand 118 motor cortex hotspot at 110% of each participant's RMT. The resulting MEP amplitude and SP 119 duration in the contralateral APB muscle were measured. Five to six replicates were performed 120 per session, with care taken to avoid fatigue between replicates. Participants completed 7 121 sessions on different days involving SP, apart from three individuals who withdrew from the 122 study before completion (one AB participant completed 6 sessions, one SCI participant 123 completed 3 sessions, and one SCI participant completed 2 sessions).

To quantify SP<sub>DUR</sub>, SP onset was visually defined as the end of the TMS-induced MEP, and SP
 offset was visually defined as the earliest resumption of pre-TMS EMG activity<sup>3</sup> (Figure 1).

We defined an "SP interruption" as a spike in EMG activity surrounded by SP silence, where the duration of interruption was less than 20 ms, and the absolute amplitude from one peak to the adjacent trough was at least 25% of the largest amplitude found during the 100 ms preceding the TMS impulse.

130 **2.7** Analysis – Outcomes: The primary dependent variables were MEP amplitude (mV) at rest 131 (MEP<sub>REST</sub>) and during SP elicitation (MEP<sub>ACTIVE</sub>), SP duration (ms) (SP<sub>DUR</sub>), and RMT (% 132 maximum stimulator output). SP interruptions were an exploratory outcome. For each 133 participant, within-session means were computed from the 5-6 replicates of each test, then 134 averaged across sessions. Before group comparisons, each outcome was first tested for 135 normality using the Shapiro-Wilks test. Normally distributed values (MEP<sub>ACTIVE</sub>, SP<sub>DUR</sub>, and 136 RMT) were compared between AB and SCI groups using independent-sample t-tests. Non-137 normally distributed values (MEP<sub>REST</sub>) were compared using an independent-samples Mann-138 Whitney U test.

139

140 <u>Variability</u>: Within-session coefficients of variation (CV) were computed for each participant from 141 the 5-6 replicates of each test, then averaged across sessions<sup>20</sup>. Note that RMT was only 142 determined once per session, so it was not possible to determine within-session RMT variability. 143 Between-session CVs were computed from the session means of each test. CVs were then 144 averaged across participants within each group. As CV values were not normally distributed, the

145 non-parametric related-samples Friedman's two-way analysis of variance by ranks test was 146 applied to compare CVs across outcomes within each group. Significant values on Friedman's 147 test were analyzed post-hoc between pairs of outcomes using related-samples Wilcoxon signed 148 rank tests. 149 150 Interruptions: A chi-squared test was used to compare the frequency of participants with 151 interrupted SPs between groups. As interruption values were not normally distributed, the non-152 parametric Mann-Whitney U test was used to compare number of interruptions per participant 153 between groups. 154 155 Due to testing multiple comparisons, a p value of <0.01 was used to determine significance. 156 157 Excel (Microsoft, Redmond, Washington, USA) and SPSS Version 25 (IBM, Armonk, New York, 158 USA) were used for all analyses. 159 160 Individual-level data is included as Supplementary Data 1 (by participant, averaged across 161 sessions) and Supplementary Data 2 (by participant per session). 162 163 164 165 **3 Results** 

- **3.1 Participants -** 21 individuals (12 AB and 9 SCI; 17 males, 4 females) participated in this
- 167 study (Table 1). Participants ranged in age from 22 to 64 years old. Of the 9 SCI participants,
- 168 eight had traumatic SCI, one had idiopathic transverse myelitis.
- **Table 1A SCI Demographics**

			Etiology	DOI		ISNCSCI	TMS
ID	Gender	Gender Age	of Injury	(Voors)	LOI	Grada	Threshold
			or injury	(Tears)		Glade	(% MSO)
1	М	29	Т	3	C8	С	45.9
2	М	52	Т	17	C8	С	35.8
18	М	64	Т	14	C4	D	59.4
23	М	57	Т	12	C4	D	60.8
27	М	40	Т	14	C4	D	69.7
28	М	42	Т	16	C5	D	65.9
31	М	54	Т	6	C5	С	52.7
34	F	52	Т	16	C4	В	72.0
39	F	22	NT	1	C5	С	30.0
Totals	7M, 2F	45.8 (22-64)	8T, 1NT	11 (1-17)	C4-C8	1B, 4C, 4D	54.7 (30.0-72.0)

**Table 1B – AB Demographics** 

			TMS Threshold
ID	Gender	Age	(% MSO)
			(//////////////////////////////////////
5	М	25	35.1
8	М	27	34.1
9	М	44	35.9
11	F	22	38.2
12	F	23	30.6
14	М	44	32.6
15	М	45	44.4
16	М	24	52.3
22	М	58	53.9
25	М	55	41.9
36	М	23	32.6
38	М	22	53.0
Totals	10M, 2F	34.3 (22-58)	40.4 (30.6-53.9)

Table 1. Participant demographics. A) SCI. Etiology of Injury – traumatic (T) or not traumatic
(NT); DOI – duration of injury; LOI – neurological level of injury; ISNCSCI – International
Standards for the Neurological Classification of SCI; %MSO – percent of maximal stimulator
output (average across sessions). B) AB.

177

3.2 SP duration – SCI participants had mean (SEM) SP duration of 111.40 (18.39) ms; range
46.90 – 216.17 ms, whereas AB participants had SP duration of 97.99 (9.88) ms; range 35.30 –
152.86 ms (non-significant, independent-sample t-test) (Table 2).

**3.3 Resting motor threshold** – SCI participants showed a tendency toward higher mean
(SEM) RMTs (54.69 (4.94)% maximum stimulator output; range 30.0 – 72.0) than AB
participants (40.37 (2.48)% maximum stimulator output, range 30.6 – 53.9) (p=0.012,
independent-sample t-test) (Table 2).

**3.4 MEP amplitudes** – SCI participants showed significantly lower mean (SEM) MEP<sub>REST</sub> amplitudes (0.148 (0.018) mV) than AB participants (0.462 (0.094) mV) (p<0.0005 independentsamples Mann-Whitney U test). SCI participants showed significantly lower MEP<sub>ACTIVE</sub> amplitudes (0.700 (0.133) mV) than AB participants (2.305 (0.233) mV) (p<0.0005 independentsample t-test) (Table 2).

- 191
- 192 **Table 2**

Outcome	AB (n=12)	SCI (n=9)
RMT (%	<b>40.37</b> (2.48)	
MSO)		<b>54.69</b> (4.94)
SP <sub>DUR</sub>		
(ms)	<b>97.99</b> (9.88)	<b>111.4</b> (18.39)
MEP <sub>REST</sub>	<b>0.462</b> (0.094)	<b>0.148</b> (0.018)

(mV)*		
MEPACTIVE		
(mV) *	<b>2.305</b> (0.233)	<b>0.700</b> (0.133)

Table 2 – Between-group comparisons. Means across sessions (S.E.M.). RMT, resting motor
 threshold. % MSO, percent maximum stimulator output. SP<sub>DUR</sub>, SP duration. ms, milliseconds.
 MEP<sub>REST</sub>, amplitude of resting motor evoked potential. mV, millivolts. MEP<sub>ACTIVE</sub>, amplitude of
 active motor evoked potential. \*, statistically significant between-group difference.

197

198 3.5 Intraindividual variability within sessions (Table 3, Figure 2A) - In AB volunteers, the 199 within-session CV (SEM) was 13.05 (1.40) for SP<sub>DUR</sub>, 59.79 (4.49) for MEP<sub>REST</sub>, and 21.83 200 (1.78) for MEP<sub>ACTIVE</sub> (p<0.0005 on related-samples Friedman's two-way analysis of variance by 201 ranks test). Post hoc pairwise comparisons showed that SP<sub>DUR</sub> had significantly lower within-202 session CV than both MEP<sub>REST</sub> (p=0.002 on related-samples Wilcoxon signed rank test) and 203 MEP<sub>ACTIVE</sub> (p=0.005 on related-samples Wilcoxon signed rank test). In SCI participants, the CV 204 was 16.08 (2.56) for SP<sub>DUR</sub>, 52.93 (6.18) for MEP<sub>REST</sub>, and 28.38 (2.64) for MEP<sub>ACTIVE</sub> (p<0.0005 205 on related-samples Friedman's two-way analysis of variance by ranks test). Post hoc pairwise 206 comparisons showed that SP<sub>DUR</sub> had significantly lower within-session CV than MEP<sub>REST</sub> (p=0.008 on related-samples Wilcoxon signed rank test) but not MEPACTIVE (p=0.028 on related-207 208 samples Wilcoxon signed rank test). Thus, SP<sub>DUR</sub> has lower within-session variability than MEP 209 amplitudes in both able-bodied and SCI individuals. Variability did not significantly differ 210 between AB and SCI groups.

211

# 212 Table 3

	Group		Between-	
Outcome		Within-session	session	
	AB		<b>6.96</b> (0.69)	
RMT	SCI		<b>9.19</b> (1.21)	
	AB	<b>13.05</b> (1.40)	<b>19.61</b> (2.67) <b>‡</b>	
SP <sub>DUR</sub>	SCI	<b>16.08</b> (2.56)	<b>28.50</b> (5.30) <b>‡</b>	
	AB	<b>59.79</b> (4.49) *	<b>52.04</b> (6.32) * <b>‡</b>	
MEP <sub>REST</sub>	SCI	<b>52.93</b> (6.18) *	<b>45.08</b> (6.90)	
	AB	<b>21.83</b> (1.78) *	<b>33.58</b> (4.12) <b>‡</b>	
MEPACTIVE	SCI	<b>28.38</b> (2.64)	<b>35.06</b> (3.63) <b>‡</b>	

213 **Table 3 – Outcome variability.** Coefficients of variation (S.E.M.) for AB and SCI groups. \*,

statistically significant difference between SP<sub>DUR</sub> and other outcomes within each group. *‡*,
statistically significant difference between RMT and other outcomes within each group.

217 3.6 Intraindividual variability across sessions (Table 3, Figure 2B) - In AB volunteers, the 218 between-session CV was 19.61 (2.67) for SP<sub>DUR</sub>, 52.04 (6.32) for MEP<sub>REST</sub>, 33.58 (4.12) for 219 MEP<sub>ACTIVE</sub>, and 6.96 (0.69) for RMT (p<0.0005 on related-samples Friedman's two-way analysis 220 of variance by ranks test). Post hoc pairwise comparisons showed that SP<sub>DUR</sub> had significantly 221 lower between-session CV than MEP<sub>REST</sub> (p=0.002 on related-samples Wilcoxon signed rank 222 test) but not MEP<sub>ACTIVE</sub> (p=0.019 on related-samples Wilcoxon signed rank test), and 223 significantly higher between-session CV than RMT (p=0.004 on related-samples Wilcoxon 224 signed rank test). In SCI participants, the CV was 28.50 (5.30) for SP<sub>DUR</sub>, 45.08 (6.90) for 225 MEP<sub>REST</sub>, 35.06 (3.63) for MEP<sub>ACTIVE</sub>, and 9.19 (1.21) for RMT (p<0.0005 on related-samples 226 Friedman's two-way analysis of variance by ranks test). Post hoc pairwise comparisons showed 227 that SP<sub>DUR</sub> had a non-significant trend toward lower between-session CV than MEP<sub>REST</sub> 228 (p=0.086 on related-samples Wilcoxon signed rank test), and no significant difference from 229 MEP<sub>ACTIVE</sub> (p=0.314 on related-samples Wilcoxon signed rank test). SP<sub>DUR</sub> had a trend toward 230 higher between-session CV than RMT (p=0.015 on related-samples Wilcoxon signed rank test) 231 in SCI participants. There was no difference in between-session CV between AB and SCI 232 participants. Thus, SP<sub>DUR</sub> had significantly lower between-session variability than MEP 233 amplitudes in able-bodied but not SCI individuals. However, RMT values were clearly more 234 reliable across sessions than SP duration or MEP amplitudes.

235

3.7 SP Interruptions – 3 out of 12 AB participants and 8 out of 9 SCI participants showed
interrupted SPs (p =0.004; Pearson chi-square test). Per session, AB volunteers showed 0.089
(0.71) interruptions, while SCI volunteers showed 1.781 (0.787) interruptions (p=0.001 on

independent-samples Mann-Whitney U test) (Figure 3). From the perspective of individual SP
 trials, there were five interrupted CSPs out of 467 total CSP events (1.07%) in AB participants,

and 52 interrupted CSPs out of 242 total CSP events (21.5%) in SCI participants.

- 242
- 243

### 244 **4 Discussion**

245 The current study measured corticospinal excitatory and inhibitory pathways as reflected 246 by MEP amplitude and SP duration, respectively, in individuals with and without SCI. Our data 247 confirm the well-known finding that SCI individuals have higher TMS motor thresholds and lower 248 MEP amplitudes than able-bodied volunteers, indicating reduced excitability of the motor cortex, 249 reduced corticospinal transmission, reduced excitability of local spinal circuitry, or any 250 combination thereof. Due to large variability between individuals, we found no significant 251 difference in SP duration between SCI and able-bodied participants. Importantly, variability 252 within individuals of SP duration is lower than variability of MEP amplitude, suggesting that SP 253 duration may be a useful outcome measure with higher signal-to-noise ratio.

Appropriate movement requires inhibitory neural feedback as well as neural excitation. Consequently, imbalance between neural excitation and inhibition may contribute to the failure in restoration of useful motor function after SCI. Whereas MEP amplitude is usually regarded as an excitatory readout and SP duration as an inhibitory readout, both measures reflect a complex relationship between excitatory and inhibitory neurophysiology and clinical pathophysiology. A prolonged SP has been reported in a number of cerebral pathologies such as stroke<sup>9</sup>,

260 epilepsy<sup>10</sup>, and depression<sup>11</sup>. On the other hand, shortened SP duration has been reported in 261 bipolar disorder<sup>12</sup>, Parkinson's<sup>21</sup>, Alzheimer's disease<sup>22</sup>, and chronic neuropathic pain<sup>13</sup>.

262 Thus, lesions affecting the cortex, corticospinal tract, or segmental spinal circuits may 263 affect SP duration in opposing fashion. Further complicating the interpretation of SP duration, a 264 variety of experimental factors affect SP. In our study, we examined SP duration in the context 265 of a maximal-effort pincer grip between the thumb and third finger, with a relatively low TMS 266 intensity (110% of RMT). SP duration correlates positively with increases in TMS intensity, but does not correlate with level of volitional contraction<sup>3,23</sup>. SP duration is also highly task 267 268 dependent. In young adults, the fractionated task of abducting the index finger demonstrated 269 longer SP duration than a task involving pincer grip between the thumb and index finger, which demonstrated longer SP duration than a task involving power grip<sup>24</sup>. This suggests an inverse 270 correlation between SP duration and the number of muscles used for a task<sup>4</sup>. Another study in 271 272 healthy adults showed that increasing amounts of sensory afferent input shortened SP duration<sup>25</sup>. These studies demonstrated the importance of afferent feedback in downwardly 273 274 modulating SP duration, presumably by inhibiting the cortical GABAergic interneurons that 275 mediate SP<sup>15</sup>. Thus, SCI would be expected to prolong SP duration due to reduced afferent 276 feedback through the lesioned cord.

Our study did not show a significant difference in SP duration between SCI and AB participants. We speculate that the relatively low TMS intensity used in our study contributed to shorter SP duration and increased variability between individuals, reducing sensitivity to detect differences<sup>20</sup>. Prior investigation of SP in the SCI population has been limited. In six participants after thoracolumbar SCI, SP duration in hand muscles above the lesion increased (APB muscle,

<sup>282</sup> "gentle" pincer effort; TMS intensity at 140-180% RMT), MEP amplitudes decreased, and <sup>283</sup> cortical motor map representations shifted<sup>14</sup>. The altered cortical maps in this study, as well as <sup>284</sup> the observed changes in muscles rostral to the spinal lesion level, suggested that these <sup>285</sup> neurophysiological changes after SCI were cortical in origin.

286 Likewise, a study of 16 participants with chronic cervical SCI relative to 18 uninjured 287 controls showed prolonged SP duration (FDI muscle, 25% effort, TMS intensity set to produce 288 similar MEP amplitude across participants) after SCI, regardless of oral baclofen intake'. The 289 difference in SP duration seen by Barry and colleagues was observed when evoked by TMS but 290 not when evoked by transcranial electrical stimulation (TES) - since TMS activates corticospinal 291 neurons indirectly through cortical interneurons, this discrepancy between TMS and TES 292 pointed to cortical mechanisms for SP elongation after SCI. A study of nine males with chronic 293 cervical SCI observed prolonged SP (extensor digitalis communis muscle, 10% effort, TMS 294 intensity at 110% AMT), increased motor thresholds, and shifted cortical maps relative to 295 uninjured controls<sup>16</sup>. Participants with greater spinal cord atrophy in that study showed relatively 296 greater changes in SP and motor thresholds, suggesting that corticospinal transmission and 297 local cord circuitry contributed to the observed neurophysiological changes.

298 On the contrary, a study of three individuals with cervical SCI showed loss of SP in two 299 of three hand muscles and all three foot muscles (50% effort, TMS intensity at 100% of 300 stimulator output)<sup>17</sup>. The authors speculated that SP loss derived from abnormal ascending 301 sensory activity leading to cortical hyperexcitability, and/or increased local spinal neuronal 302 excitability.

303 Our findings of decreased coefficients of variation in SP duration relative to MEP 304 amplitude support the contention that SP duration may be a more reliable TMS metric than MEP 305 amplitude. One other study measured MEPs and SP across time in individuals with chronic 306 incomplete tetraplegia<sup>18</sup>. In that study, SP duration had relatively high reliability for both stronger 307 and weaker muscles, whereas MEP amplitude had medium reliability for stronger muscles and 308 poor reliability for weaker muscles. Studies in able-bodied participants provide further evidence that SP duration is more reliable across sessions than between individuals<sup>20</sup>. Importantly, 309 310 resting motor threshold, which is determined at the beginning of any experimental TMS session. 311 showed the least between-session variability of the measures we examined. Resting motor 312 threshold demonstrated the lowest variability of multiple TMS measures in a study of elderly 313 individuals with and without stroke<sup>26</sup>. It remains to be determined whether motor threshold is 314 more sensitive than other measures to detecting changes after interventions aimed to increase 315 central neural transmission in people with SCI.

316 We observed an overwhelmingly higher prevalence of SP 'interruption' frequency in SCI 317 relative to AB participants. These short (<20 ms) periods of EMG activity in the midst of the SP 318 appear similar to 'late excitatory potentials (LEP)' noted by Wilson et al<sup>27</sup> and 'breakthrough 319 EMG activity' discussed by Hupfeld at al<sup>4</sup>. Intra-SP EMG activity has been hypothesized to 320 originate from two sources: muscle spindle-gamma motoneuron reflex activity in response to muscle lengthening during the SP; and transient cortical disinhibition<sup>27</sup>. Caudal to the lesion, 321 322 increased spindle-mediated reflex activity is well documented after SCI. At the lesion, 323 fasciculations of individual motor units represent spontaneous hyperexcitable discharges in

upper extremity muscles commonly seen after cervical SCI<sup>28</sup>. Therefore, it is not surprising that
 SCI participants demonstrated a much higher SP interruption rate than AB participants.

326 Our study has several important limitations: Due to time constraints, only 5-6 SP trials 327 were collected per session, less than the roughly 20 trials needed to maximize reliability of most 328 TMS measures<sup>4,29</sup>. The SCI group was older than the control group. A majority of past studies 329 suggest that age negatively correlates with SP duration, which would mean that the results of 330 this study may underestimate the true difference in SP duration between SCI and non-SCI groups<sup>4</sup>. Individuals in the SCI group were more likely to be taking oral baclofen or other neural 331 332 inhibitory medications. However, unlike intrathecal baclofen, oral baclofen has not clearly been shown to affect SP duration<sup>7,8</sup>. Furthermore, individuals with SCI have obviously lower ability to 333 334 contract target muscles than non-SCI participants during SP elicitation. However, this would be 335 the case whether at maximal effort or at any set percentage of an individual's volitional effort, and muscle contraction intensity does not play a major role in SP duration regardless<sup>3,23</sup>. TMS 336 337 intensity during SP measurements was at 110% of resting motor threshold - most studies have 338 used higher TMS intensities, which is a key factor in longer SP duration and may reduce intersession variability<sup>3,20,23</sup>. 339

340

### 341 Conclusion

In individuals with chronic cervical SCI relative to able-bodied controls, we confirmed the well-known findings that SCI individuals have lower TMS evoked potential amplitudes and a tendency toward higher TMS motor thresholds. We did not observe significantly longer SP duration in SCI individuals. Importantly, we observed significantly lower within-person variability

346	of SP duration than within-person variability of TMS response amplitude, suggesting that SP						
347	duration may be a useful outcome measure with higher signal-to-noise ratio. Ongoing and future						
348	studies in our lab will further investigate silent periods induced by either cortical or cutaneous						
349	stimulation <sup>30</sup> to correlate EMG with electroencephalographic features and shed more						
350	mechanistic insight into these phenomena.						
351							
352	Data Archiving: Individual-level data is included as Supplementary Data 1 (by participant,						
353	averaged across sessions) and Supplementary Data 2 (by participant per session). All						
354	deidentified data is freely available to any investigator upon request.						
355							
356	Statement of Ethics: All procedures were approved by the Institutional Review Board of the						
357	James J. Peters VA Medical Center, Bronx, NY (HAR-15-001). We certify that all applicable						
358	institutional and governmental regulations concerning the ethical participation of human						
359	volunteers were followed during the course of this research.						
360							
361	Conflicts of Interest: The authors declare no conflicts of interest.						
362							
363	Author Contributions:						
364	HJS: Data acquisition; data interpretation; manuscript drafting and revision						

- 365 JRW: Data acquisition; data interpretation; manuscript drafting and revision

- 366 OA: Data interpretation; manuscript revision
- 367 YKW: Data acquisition; data interpretation; manuscript revision
- 368 NYH: Study conception and design; data interpretation; manuscript drafting and revision.

369

- 370 Sources of Funding: New York State Department of Health C30599. Craig H. Neilsen
- 371 Foundation 457648.

373

## 374 References

- 1. Fuhr, P., Agostino, R. & Hallett, M. Spinal motor neuron excitability during the silent
- 376 period after cortical stimulation. *Electroencephalogr. Clin. Neurophysiol. Evoked*
- 377 *Potentials* **81**, 257–262 (1991).
- Poston, B., Kukke, S. N., Paine, R. W., Francis, S. & Hallett, M. Cortical silent period
   duration and its implications for surround inhibition of a hand muscle. *Eur. J. Neurosci.*
- **36**, 2964–2971 (2012).
- 381 3. Inghilleri, M., Berardelli, A., Cruccu, G. & Manfredi, M. Silent period evoked by
- 382 transcranial stimulation of the human cortex and cervicomedullary junction. *J. Physiol.*383 466, 521–534 (1993).
- Hupfeld, K. E., Swanson, C. W., Fling, B. W. & Seidler, R. D. TMS-induced silent periods:
   A review of methods and call for consistency. *Journal of Neuroscience Methods* 346,
   (2020).
- 387 5. Inghilleri, M., Berardelli, A., Marchetti, P. & Manfredi, M. Effects of diazepam, baclofen
- 388 and thiopental on the silent period evoked by transcranial magnetic stimulation in
- 389 humans. *Exp. Brain Res.* **109**, 467–472 (1996).
- 390 6. Stetkarova, I. & Kofler, M. Differential effect of baclofen on cortical and spinal inhibitory
  391 circuits. *Clin. Neurophysiol.* **124**, 339–345 (2013).
- 392 7. Barry, M. D., Bunday, K. L., Chen, R. & Perez, M. A. Selective effects of baclofen on use393 dependent modulation of GABAB inhibition after tetraplegia. *J. Neurosci.* 33, 12898–907
  394 (2013).

395	8.	McDonnell, M.	N., Orekhov.	. Y. & Ziemann.	U. The	role of GABA	B receptors in
				,			

- intracortical inhibition in the human motor cortex. *Exp. Brain Res.* **173**, 86–93 (2006).
- 397 9. Braune, H. J. & Fritz, C. Transcranial magnetic stimulation-evoked inhibition of voluntary
- 398 muscle activity (silent period) is impaired in patients with ischemic hemispheric lesion.
- 399 Stroke **26**, 550–553 (1995).
- 400 10. Macdonell, R. A. *et al.* Prolonged cortical silent period after transcranial magnetic
- 401 stimulation in generalized epilepsy. *Neurology* **57**, 706–8 (2001).
- 402 11. Steele, J. D., Glabus, M. F., Shajahan, P. M. & Ebmeier, K. P. Increased cortical
- 403 inhibition in depression: A prolonged silent period with transcranial magnetic stimulation
- 404 (TMS). *Psychol. Med.* **30**, 565–570 (2000).
- 405 12. Levinson, A. J., Young, L. T., Fitzgerald, P. B. & Daskalakis, Z. J. Cortical inhibitory
- 406 dysfunction in bipolar disorder: A study using transcranial magnetic stimulation. *J. Clin.*
- 407 *Psychopharmacol.* **27**, 493–497 (2007).
- 408 13. Lefaucheur, J. P., Drouot, X., Ménard-Lefaucheur, I., Keravel, Y. & Nguyen, J. P. Motor
- 409 cortex rTMS restores defective intracortical inhibition in chronic neuropathic pain.
- 410 *Neurology* **67**, 1568–1574 (2006).
- 411 14. Lotze, M., Laubis-Herrmann, U. & Topka, H. Combination of TMS and fMRI reveals a
- 412 specific pattern of reorganization in M1 in patients after complete spinal cord injury.
- 413 *Restor Neurol Neurosci* **24**, 97–107 (2006).
- 414 15. Nardone, R. *et al.* Motor cortex excitability changes following a lesion in the posterior
- 415 columns of the cervical spinal cord. *Neurosci. Lett.* **434**, 119–123 (2008).
- 416 16. Freund, P., Rothwell, J. C., Craggs, M., Thompson, A. J. & Bestmann, S. Corticomotor

- 417 representation to a human forearm muscle changes following cervical spinal cord injury.
- 418 *Eur. J. Neurosci.* **34**, 1–8 (2011).
- 419 17. Shimizu, T., Hino, T., Komori, T. & Hirai, S. Loss of the muscle silent period evoked by
- 420 transcranial magnetic stimulation of the motor cortex in patients with cervical cord lesions.
- 421 *Neurosci. Lett.* **286**, 199–202 (2000).
- 422 18. Potter-Baker, K. A. *et al.* Reliability of TMS metrics in patients with chronic incomplete
  423 spinal cord injury. *Spinal Cord* 54, 980–990 (2016).
- 424 19. Wu, Y.-K. *et al.* Posteroanterior cervical transcutaneous spinal stimulation targets ventral
- 425 and dorsal nerve roots. *Clin. Neurophysiol. International Federation of Clinical*
- 426 *Neurophysiology* **131**, 451–460 (2020).
- 427 20. Orth, M. & Rothwell, J. C. The cortical silent period: Intrinsic variability and relation to the
- 428 waveform of the transcranial magnetic stimulation pulse. *Clin. Neurophysiol.* **115**, 1076–
  429 1082 (2004).
- 430 21. Nakashima, K., Wang, Y., Shimoda, M., Sakuma, K. & Takahashi, K. Shortened silent
- 431 period produced by magnetic cortical stimulation in patients with Parkinson's disease. J.
- 432 *Neurol. Sci.* **130**, 209–214 (1995).
- 433 22. Alagona, G. *et al.* Transcranial magnetic stimulation in Alzheimer disease: Motor cortex
  434 excitability and cognitive severity. *Neurosci. Lett.* **314**, 57–60 (2001).
- 435 23. Kojima, S. et al. Modulation of the cortical silent period elicited by single- and paired-
- 436 pulse transcranial magnetic stimulation. *BMC Neurosci.* **14**, (2013).
- 437 24. Tinazzi, M. *et al.* Task-dependent modulation of excitatory and inhibitory functions within
  438 the human primary motor cortex. *Exp. Brain Res.* **150**, 222–229 (2003).

- 439 25. Hess, A. *et al.* Task-dependent modulation of inhibitory actions within the primary motor
  440 cortex. *Exp. Brain Res.* **124**, 321–330 (1999).
- 441 26. Schambra, H. M. et al. The reliability of repeated TMS measures in older adults and in
- 442 patients with subacute and chronic stroke. *Front. Cell. Neurosci.* **9**, (2015).
- 443 27. Wilson, S. A., Thickbroom, G. W. & Mastaglia, F. L. An investigation of the late excitatory
- 444 potential in the hand following magnetic stimulation of the motor cortex.
- 445 Electroencephalogr. Clin. Neurophysiol. Electromyogr. 97, 55–62 (1995).
- 446 28. Grapperon, A. M. & Attarian, S. Disorders of motor neurons manifested by hyperactivity.
- 447 *Revue Neurologique* **173**, 345–351 (2017).
- 448 29. Nguyen, D. T. A., Rissanen, S. M., Julkunen, P., Kallioniemi, E. & Karjalainen, P. A.
- 449 Principal Component Regression on Motor Evoked Potential in Single-Pulse Transcranial
- 450 Magnetic Stimulation. *IEEE Trans. Neural Syst. Rehabil. Eng.* **27**, 1521–1528 (2019).
- 451 30. Tadokoro, N. *et al.* Discrepancy between functional recovery and cutaneous silent period
- 452 change in surgically treated degenerative cervical myelopathy: a prospective pilot study.
- 453 Spinal Cord **57**, 1076–1083 (2019).
- 454

### 455 Legends

456

Figure 1 – Schematic and examples of silent period. A) TMS is delivered (red arrow) to the hand motor cortex while the participant performs a volitional isometric pinch with the contralateral hand. The resulting MEP (black arrow) is followed by an EMG silent period before the resumption of baseline volitional EMG activity. B) Representative silent period in ablebodied volunteer. C) Representative silent period in SCI participant. Note lower EMG amplitudes and presence of 'interruption' (green arrow). APB, abductor pollicis brevis.

Figure 2 – Outcome variability. A) Within-session coefficient of variation for each group. B)
Between-session coefficient of variation for each group. Error bars represent S.E.M. \*,
significantly different from SP duration; ‡, significantly different from RMT.

467

Figure 3 – SP interruptions by group and participant. The average number of interruptions
 per session for each participant. Error bars represent S.D.

470

471 Supplementary Data 1 – Participant-level data averaged across sessions.

472 InterssNum, number of interruptions per session; CVSPdurIntra, intrasession coefficient of

473 variation for SP<sub>DUR</sub>; CVMEPrestIntra, intrasession coefficient of variation for MEP<sub>REST</sub>;

474 CVMEPactiveIntra, intrasession coefficient of variation for MEP<sub>ACTIVE</sub>; CVRMTInter, intersession

475 coefficient of variation for RMT; CVSPdurInter, intersession coefficient of variation for SP<sub>DUR</sub>;

- 476 CVMEPrestInter, intersession coefficient of variation for MEP<sub>REST</sub>; CVMEPactiveInter,
- 477 intersession coefficient of variation for MEP<sub>ACTIVE</sub>.
- 478

# 479 Supplementary Data 2 – Participant-level data listed per session.

- 480
- 481
- 482
- 483







